Intended for healthcare professionals

  1. Research
  2. Mortality risk during...
  3. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies
CCBYNC Open access
Research

Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies

BMJ 2017; 357 doi: https://doi.org/10.1136/bmj.j1550 (Published 26 April 2017) Cite this as: BMJ 2017;357:j1550

Data supplement

Related articles

EditorialOpioid substitution treatment and risk of death

See more

Cited by...

  • Principles of Care for Young Adults With Substance Use Disorders
  • Evidence-Based Treatment of Young Adults With Substance Use Disorders
  • Scoping review protocol: the use of telemedicine in providing opioid agonist treatment and related psychosocial supports
  • Medication Improves Age Disparities in Six-Month Treatment Retention for Opioid Use Disorder
  • The Concurrent Initiation of Medications Is Associated with Discontinuation of Buprenorphine Treatment for Opioid Use Disorder
  • Financing Buprenorphine Treatment in Primary Care: A Microsimulation Model
  • Rise and Regional Disparities in Buprenorphine Utilization in the United States
  • Lignes directrices de pratique clinique pour les personnes sans-abri, logees precairement, ou ayant connu litinerance
  • Comparative effectiveness of buprenorphine-naloxone versus methadone for treatment of opioid use disorder: a population-based observational study protocol in British Columbia, Canada
  • Toxicology and prescribed medication histories among people experiencing fatal illicit drug overdose in British Columbia, Canada
  • Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: population based retrospective cohort study
  • Management of dependent use of illicit opioids
  • Clinical guideline for homeless and vulnerably housed people, and people with lived homelessness experience
  • Opioid agonist therapy during residential treatment of opioid use disorder: Cohort study on access and outcomes
  • Injectable opioid agonist treatment for opioid use disorder: a national clinical guideline
  • La crise cachee des opioides au Canada : lincapacite du systeme de sante de gerer les patients prenant de fortes doses dopioides: Repercussions des recommandations canadiennes de 2017 sur les opioides
  • Canadas hidden opioid crisis: the health care systems inability to manage high-dose opioid patients: Fallout from the 2017 Canadian opioid guidelines
  • Supporting Physicians and Practice Teams in Efforts to Address the Opioid Epidemic
  • Quality of primary care among individuals receiving treatment for opioid use disorder
  • Patient-centred care in opioid agonist treatment could improve outcomes
  • Slow release oral morphine versus methadone for the treatment of opioid use disorder
  • Youth and the Opioid Epidemic
  • Are New Residency Graduates Prepared to Treat Opioid Use Disorder?
  • Using routinely collected data to understand and predict adverse outcomes in opioid agonist treatment: Protocol for the Opioid Agonist Treatment Safety (OATS) Study
  • Improving wait time from referral to opiate replacement therapy in a drug recovery service
  • The 2017 Canadian opioid guideline: already time for an overhaul
  • Narrowing the treatment gap in managing opioid use disorder
  • Management of opioid use disorders: a national clinical practice guideline
  • Suboxone: Rationale, Science, Misconceptions
  • Availability of naloxone in Canadian pharmacies:a population-based survey
  • Opioid agonist therapy
  • Opioid substitution treatment is linked to reduced risk of death in opioid use disorder
Back to top